Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Stille AB's Debt-to-EBITDA or its related term are showing as below:
OSTO:STIL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.89 Max: 2.82
Current: 1.13
During the past 13 years, the highest Debt-to-EBITDA Ratio of Stille AB was 2.82. The lowest was 0.03. And the median was 0.89.
OSTO:STIL's Debt-to-EBITDA is ranked better than 55.46% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs OSTO:STIL: 1.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Stille AB Debt-to-EBITDA Related Terms
Stille AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Stille AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:STIL vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Stille AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stille AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stille AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stille AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Stille AB (OSTO:STIL) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Stille AB. Over the past decade, Stille AB's Debt-to-EBITDA has ranged from 0.03 to 2.82. According to the industry distribution chart, Stille AB ranks #208 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 44.5%.
Is Stille AB's Debt-to-EBITDA too high?
Stille AB's current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 2.82. Based on the distribution chart, Stille AB ranks #208 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Stille AB has a GF Score™ of 99/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stille AB's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Stille AB ranks #208 out of 467 companies for Debt-to-EBITDA. This puts Stille AB in the upper half of its industry. The industry median Debt-to-EBITDA is 1.60. Historically, Stille AB's own Debt-to-EBITDA has ranged from 0.03 to 2.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Stille AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stille AB's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stille AB stock overvalued right now?
Based on GuruFocus' analysis, Stille AB (OSTO:STIL) is currently considered Fairly Valued. The stock's GF Value™ is kr255.75, compared to a current price of kr252.00 — trading 1.5% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Stille AB's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Stille AB (OSTO:STIL), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stille AB (OSTO:STIL) Overvalued in 2026?
Based on GuruFocus' analysis, Stille AB stock appears to be undervalued.
The current stock price of kr252.00 is trading 1.5% below its estimated GF Value™ of kr255.75.
GuruFocus considers Stille AB to be Fairly Valued.
Key valuation signals for OSTO:STIL:
Debt-to-EBITDA: 0.00
GF Value™: kr255.75 vs. price of kr252.00 (1.5% below fair value)
No single metric tells the full story. See the OSTO:STIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stille AB manufactures and distributes medical devices. Its products include surgical equipment such as Surgical Scissors, Forceps, Curettes, Raspatories, Elevators, c-arm tables and instrument care education, among others.
99GF Score
Get the complete analysis for OSTO:STIL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:STIL has been successfully added to your 
